MoneyTreeTM: Pharmaceuticals and life sciences second quarter gains fade
Life sciences venture capital (VC) investment remains on pace to surpass 2009 levels but activity and investment in the third quarter of 2010 declined from the previous quarter. Life sciences funding for Q3 2010 totaled $1.52 billion and accounted for 190 deals. Despite the drop off, the life sciences sector, which is comprised of the biotechnology and medical device industries, continued to capture the largest share of funding.
This summary of life sciences third quarter investment trends, includes findings from the MoneyTree Report by PwC and the National Venture Capital Association (NVCA), based on data from Thomson Reuters.
Look for papers, articles, and case studies. See all thought leadership.